Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Liver-Directed chemo may shrink tumors enough for surgery in colorectal cancer

NCT ID NCT00492999

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether delivering chemotherapy directly into the liver (hepatic arterial infusion) along with standard IV chemo can shrink inoperable liver tumors from colorectal cancer enough to allow surgical removal. The study involves 64 participants whose cancer has spread only to the liver. The goal is to see how many patients become eligible for liver surgery, which could improve their chances of long-term survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
floxuridine and dexamethasone given directly into the liver artery, plus standard IV chemotherapy
What this could lead to
If successful, this approach could make more patients eligible for liver surgery, potentially improving long-term survival for those with colorectal cancer that has spread only to the liver.
What could go wrong
This is a mid-stage trial with only 64 participants, so results may not apply broadly. The treatment involves complex procedures and strong chemotherapy, which carry risks like infection, liver damage, and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2007

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

DISEASE CHARACTERISTICS: * Histologically confirmed colorectal adenocarcinoma metastatic to the liver * Previously treated or untreated disease * No clinical or radiographic evidence of extrahepatic disease * Primary tumor may be present at study registration provided it is not obstructing the intestinal lumen or is significantly bleeding * If present, the primary tumor will be resected at the time of pump placement * Must have inoperable liver metastases confirmed by 2-3 hepatobiliary surgeons and the assigned radiologist * Liver metastases \< 70% of the liver parenchyma * Inoperable liver metastases is defined by one of the following: * More than 6 metastases in a single lobe with one lesion ≥ 5 cm * At least 6 metastases distributed diffusely in both lobes of the liver * When a margin-negative resection would require resection of all three hepatic veins, both portal veins, or the retrohepatic vena cava * Requires a resection that leaves \< 2 hepatic segments (not including the caudate lobe) behind with adequate arterial or portal inflow, venous outflow, and biliary drainage * No ascites or hepatic encephalopathy * No history of primary CNS tumors PATIENT CHARACTERISTICS: * Karnofsky performance status 60-100% * WBC ≥ 3,000/mm\^3 * ANC ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * INR \< 1.5 * Hemoglobin ≥ 9 g/dL * Creatinine ≤ 1.5 mg/dL * Total bilirubin ≤ 1.5 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Physically able to tolerate major partial hepatectomy * No active infection * No concurrent active malignancies, except potentially resectable primary colorectal tumor * No bleeding diathesis or coagulopathy * No history of serious systemic disease, including any of the following: * Myocardial infarction within the past 6 months * Uncontrolled hypertension (i.e., blood pressure \> 150/100 mm Hg on medication) * Unstable angina * New York Heart Association class II-IV congestive heart failure * Unstable symptomatic arrhythmia requiring medication * Chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed * Peripheral vascular disease ≥ grade 2 * No serious or nonhealing active wound, ulcer, or bone fracture * No history of seizures not well controlled with standard medical therapy * No stroke or transient ischemic attack within the past 6 months * No concurrent obstruction of the gastrointestinal or genitourinary tract PRIOR CONCURRENT THERAPY: * At least 4 weeks since prior radiotherapy to the pelvis * Prior chemotherapy allowed * No prior radiotherapy, hepatic thermal ablation, or resection (other than biopsy) to the liver * No prior floxuridine * No prior hepatic arterial infusion * No concurrent chronic aspirin (\> 325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit platelet function * No other concurrent investigational agents

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal adenocarcinoma metastatic to the liver are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center@Phelps Memorial Hospital

    Sleepy Hollow, New York, United States

  • Memorial Sloan Kettering at Mercy Medical Center

    Rockville Centre, New York, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.